• Results Demonstrate Safety and Long-Term Efficacy of QM1114 in 350 patients for the Treatment of Glabellar Lines
• Galderma Received Manufacturing License for its New Facilities at their Center of Excellence in Uppsala, Sweden
• Galderma Poised to Advance to Phase 3 Testing